DK2978844T3 - Modificerede tgf-beta2-oligonukleotider - Google Patents
Modificerede tgf-beta2-oligonukleotider Download PDFInfo
- Publication number
- DK2978844T3 DK2978844T3 DK14713127.0T DK14713127T DK2978844T3 DK 2978844 T3 DK2978844 T3 DK 2978844T3 DK 14713127 T DK14713127 T DK 14713127T DK 2978844 T3 DK2978844 T3 DK 2978844T3
- Authority
- DK
- Denmark
- Prior art keywords
- oligonucleotids
- beta2
- modified tgf
- tgf
- modified
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Ophthalmology & Optometry (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13161474 | 2013-03-27 | ||
EP13173078 | 2013-06-20 | ||
EP13199838 | 2013-12-30 | ||
PCT/EP2014/056232 WO2014154843A1 (en) | 2013-03-27 | 2014-03-27 | Modified tgf-beta2 oligonucleotides |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2978844T3 true DK2978844T3 (da) | 2020-11-16 |
Family
ID=50389442
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK14713127.0T DK2978844T3 (da) | 2013-03-27 | 2014-03-27 | Modificerede tgf-beta2-oligonukleotider |
Country Status (13)
Country | Link |
---|---|
US (2) | US9840707B2 (da) |
EP (1) | EP2978844B1 (da) |
JP (1) | JP6492054B2 (da) |
KR (1) | KR102108600B1 (da) |
CN (1) | CN105308182B (da) |
BR (1) | BR112015024729B1 (da) |
CA (1) | CA2908105C (da) |
DK (1) | DK2978844T3 (da) |
EA (1) | EA201591595A1 (da) |
ES (1) | ES2830051T3 (da) |
HK (1) | HK1221255A1 (da) |
PL (1) | PL2978844T3 (da) |
WO (1) | WO2014154843A1 (da) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017144685A1 (en) | 2016-02-26 | 2017-08-31 | Secarna Pharmaceuticals Gmbh & Co. Kg | Novel approach for treating inflammatory disorders |
CA3039071A1 (en) | 2016-10-07 | 2018-04-12 | Secarna Pharmaceuticals Gmbh & Co. Kg | Immunosuppression-reverting oligonucleotides inhibiting the expression of ido |
JP2019531095A (ja) * | 2016-10-07 | 2019-10-31 | セカルナ・ファーマシューティカルズ・ゲーエムベーハー・ウント・コ・カーゲー | Cd73の発現を阻害する免疫抑制復帰オリゴヌクレオチド |
CN110191952A (zh) * | 2016-10-07 | 2019-08-30 | 瑟卡尔纳制药有限公司 | 治疗癌症的新方法 |
AU2017339576A1 (en) * | 2016-10-07 | 2019-05-02 | Secarna Pharmaceuticals Gmbh & Co. Kg | Immunosuppression-reverting oligonucleotides inhibiting the expression of CD39 |
EP3538655A1 (en) * | 2016-11-11 | 2019-09-18 | ISARNA Therapeutics GmbH | Tgf-beta oligonucleotide for use in treatment of ophthalmic diseases |
EP3346007A1 (en) | 2017-01-09 | 2018-07-11 | Secarna Pharmaceuticals GmbH & Co. KG | Immunosuppression-reverting oligonucleotides inhibiting the expression of tdo |
WO2018127599A1 (en) | 2017-01-09 | 2018-07-12 | Secarna Pharmaceuticals Gmbh & Co Kg | Oligonucleotides inhibiting the expression of nrp1 |
US11781136B2 (en) | 2017-09-28 | 2023-10-10 | Secarna Pharmaceuticals Gmbh & Co. Kg | Oligonucleotide inhibiting the expression of Chop |
CN110229813B (zh) * | 2018-03-05 | 2025-01-21 | 苏州派动生物技术有限公司 | 具有疫苗佐剂作用和肿瘤治疗作用的寡核苷酸 |
WO2020011909A1 (en) | 2018-07-11 | 2020-01-16 | Secarna Pharmaceuticals Gmbh & Co. Kg | Nucleic acid polymers inhibiting the expression of xbp1 |
EP3963074A1 (en) | 2019-05-03 | 2022-03-09 | Secarna Pharmaceuticals GmbH & Co. KG | Pd-l1 antisense oligonucleotides for use in tumor treatment |
EP3791930A1 (en) | 2019-09-13 | 2021-03-17 | Secarna Pharmaceuticals GmbH & Co. KG | Inhibitor of metadherin expression |
EP3845646A1 (en) | 2019-12-30 | 2021-07-07 | Secarna Pharmaceuticals GmbH & Co. KG | Modified antisense oligonucleotide for inhibition of foxp3 expression |
JP2023524696A (ja) | 2020-04-30 | 2023-06-13 | セカルナ・ファーマシューティカルズ・ゲーエムベーハー・ウント・コ・カーゲー | Pd-1特異的アンチセンスオリゴヌクレオチド及び療法におけるその使用 |
TW202229554A (zh) | 2020-12-31 | 2022-08-01 | 中山大學附屬第一醫院 | 用於降低血管收縮素轉化酶2(ace2)之表現的寡核苷酸及其用於治療病毒感染的用途 |
CN113018508A (zh) * | 2021-03-15 | 2021-06-25 | 西安交通大学医学院第一附属医院 | 一种表面修饰的人工晶状体及其制备方法 |
TW202327628A (zh) | 2021-12-23 | 2023-07-16 | 德商瑟卡爾納製藥有限兩合公司 | 供用於預防及/或治療發炎性疾病之nlrp3寡核苷酸 |
EP4504935A2 (en) | 2022-04-08 | 2025-02-12 | Secarna Pharmaceuticals GmbH & Co. KG | Oligonucleotide for reducing the expression of leucine-rich repeat kinase 2 (lrrk2) and its use for preventing and/or treating human diseases |
WO2024218302A1 (en) | 2023-04-21 | 2024-10-24 | Secarna Pharmaceuticals Gmbh & Co. Kg | Nrp1-specific antisense oligonucleotides and their use in preventing and/or treating diseases |
WO2024227085A2 (en) * | 2023-04-26 | 2024-10-31 | Stoke Therapeutics, Inc. | Compounds and methods for treating human subjects |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE211762T1 (de) * | 1993-04-30 | 2002-01-15 | Biognostik Ges | Antisense-oligonukleotide zur behandlung des immunsuppressiven effektes des transformierenden wachstumsfaktor-beta1(tgf-beta1) |
EP1160319A3 (en) | 1993-04-30 | 2002-03-06 | BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH | Antisense-oligonucleotides for the treatment of immunosuppressive effects of transforming growth factor-beta (TGF-beta) |
US20040006030A1 (en) | 2002-07-02 | 2004-01-08 | Isis Pharmaceuticals Inc. | Antisense modulation of TGF-beta 2 expression |
EP1568383A3 (en) | 2004-02-27 | 2005-11-16 | Antisense Pharma GmbH | Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment |
WO2005084712A2 (en) * | 2004-02-27 | 2005-09-15 | Antisense Pharma Gmbh | Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment |
EP1935428A1 (en) * | 2006-12-22 | 2008-06-25 | Antisense Pharma GmbH | Oligonucleotide-polymer conjugates |
US20110119781A1 (en) * | 2008-07-15 | 2011-05-19 | Birgit Bramlage | Compositions and Methods for Inhibiting Expression of TGF-BETA Receptor Genes |
JP2013531981A (ja) * | 2010-06-11 | 2013-08-15 | アンチセンス・ファーマ・ゲーエムベーハー | 選択的オリゴヌクレオチド修飾の方法 |
EP2453017A1 (en) | 2010-11-12 | 2012-05-16 | Antisense Pharma GmbH | Oligonucleotides for use in prophylaxis and/or treatment of TGF-beta1 and TGF-beta2, TGF-beta2 and TGF-beta3, TGF-beta1 and TGF-beta3, or TGF-beta1, TGF-beta2, and TGF-beta3 mRNA overexpressing diseases |
-
2014
- 2014-03-27 EA EA201591595A patent/EA201591595A1/ru unknown
- 2014-03-27 ES ES14713127T patent/ES2830051T3/es active Active
- 2014-03-27 PL PL14713127T patent/PL2978844T3/pl unknown
- 2014-03-27 BR BR112015024729-6A patent/BR112015024729B1/pt active IP Right Grant
- 2014-03-27 EP EP14713127.0A patent/EP2978844B1/en active Active
- 2014-03-27 WO PCT/EP2014/056232 patent/WO2014154843A1/en active Application Filing
- 2014-03-27 CA CA2908105A patent/CA2908105C/en active Active
- 2014-03-27 CN CN201480030825.6A patent/CN105308182B/zh active Active
- 2014-03-27 US US14/779,945 patent/US9840707B2/en active Active
- 2014-03-27 KR KR1020157030785A patent/KR102108600B1/ko active Active
- 2014-03-27 JP JP2016504685A patent/JP6492054B2/ja active Active
- 2014-03-27 DK DK14713127.0T patent/DK2978844T3/da active
-
2016
- 2016-08-03 HK HK16109279.5A patent/HK1221255A1/zh unknown
-
2017
- 2017-12-08 US US15/836,308 patent/US20180087055A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
BR112015024729A2 (pt) | 2017-10-24 |
US9840707B2 (en) | 2017-12-12 |
CA2908105A1 (en) | 2014-10-02 |
ES2830051T3 (es) | 2021-06-02 |
CA2908105C (en) | 2021-07-27 |
PL2978844T3 (pl) | 2021-01-25 |
US20180087055A1 (en) | 2018-03-29 |
HK1221255A1 (zh) | 2017-05-26 |
CN105308182A (zh) | 2016-02-03 |
KR20150140703A (ko) | 2015-12-16 |
KR102108600B1 (ko) | 2020-05-08 |
BR112015024729B1 (pt) | 2022-02-15 |
US20160060632A1 (en) | 2016-03-03 |
EP2978844A1 (en) | 2016-02-03 |
JP6492054B2 (ja) | 2019-03-27 |
WO2014154843A1 (en) | 2014-10-02 |
CN105308182B (zh) | 2018-09-25 |
BR112015024729A8 (pt) | 2018-01-23 |
EA201591595A1 (ru) | 2016-05-31 |
EP2978844B1 (en) | 2020-08-12 |
JP2016516416A (ja) | 2016-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NL301252I2 (nl) | tislelizumab | |
NL301278I2 (nl) | vadadustat | |
DK2978844T3 (da) | Modificerede tgf-beta2-oligonukleotider | |
DK3342773T3 (da) | Syk-hæmmere | |
DK3613453T3 (da) | Fordamper | |
DK3077047T3 (da) | Aramcholsalte | |
DK2956698T5 (da) | Bindestrimler | |
DK3060460T3 (da) | Saddel | |
DK3027598T3 (da) | Oxoquinazolinyl-butanamidderivater | |
EP2952513A4 (en) | AZOLE AND BENZENE DERIVATIVE | |
DK3052081T3 (da) | Pastil | |
DK2946640T3 (da) | Langmuir-probe | |
EP2969096A4 (en) | Bottle pressurization delivery system | |
EP2991647A4 (en) | DEUTERED AMLEXANOX | |
EP2943489A4 (en) | DEUTERATED MOMELOTINIB | |
EP2970310A4 (en) | 5-BROMO-indirubins | |
DE102013106534B8 (de) | Chromatographiepipettenspitze | |
DK3071227T3 (da) | Fiskevaccine | |
FI20136125A (fi) | Rumpupulpperi | |
DE112014001252A5 (de) | Aufbissschiene | |
DK2981168T3 (da) | Laminitiskile | |
DK3086679T3 (da) | Sportssko | |
FR3008288B1 (fr) | 2sap | |
ES1078715Y (es) | Mosquitera | |
FI10779U1 (fi) | Energiapuukoura |